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Abstract
Background: Rasmussen encephalitis (RE) is a rare complex inflammatory disease, primarily seen in young children,
that is characterized by severe partial seizures and brain atrophy. Surgery is currently the only effective treatment
option. To identify genes specifically associated with the immunopathology in RE, RNA transcripts of genes involved
in inflammation and autoimmunity were measured in brain tissue from RE surgeries and compared with those in
surgical specimens of cortical dysplasia (CD), a major cause of intractable pediatric epilepsy.
Methods: Quantitative polymerase chain reactions measured the relative expression of 84 genes related to
inflammation and autoimmunity in 12 RE specimens and in the reference group of 12 CD surgical specimens. Data
were analyzed by consensus clustering using the entire dataset, and by pairwise comparison of gene expression
levels between the RE and CD cohorts using the Harrell-Davis distribution-free quantile estimator method.
Results: Consensus clustering identified six RE cases that were clearly distinguished from the CD cases and from
other RE cases. Pairwise comparison showed that seven mRNAs encoding interferon-γ, CCL5, CCL22, CCL23, CXCL9,
CXCL10, and Fas ligand were higher in the RE specimens compared with the CD specimens, whereas the mRNA
encoding hypoxanthine-guanine phosphoribosyltransferase was reduced. Interferon-γ, CXCL5, CXCL9 and CXCL10
mRNA levels negatively correlated with time from seizure onset to surgery (P <0.05), whereas CCL23 and Fas ligand
transcript levels positively correlated with the degree of tissue destruction and inflammation, respectively (P <0.05),
as determined from magnetic resonance imaging (MRI) T2 and FLAIR images. Accumulation of CD4+ lymphocytes
in leptomeninges and perivascular spaces was a prominent feature in RE specimens resected within a year of
seizure onset.
Conclusions: Active disease is characterized by a Th1 immune response that appears to involve both CD8+ and
CD4+ T cells. Our findings suggest therapeutic intervention targeting specific chemokine/chemokine receptors may
be useful in early stage RE.
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Background
Rasmussen encephalitis (RE) is an inflammatory neuro-
degenerative disease primarily seen in young children. It
is clinically characterized by intense focal and genera-
lized seizures with inflammation almost invariably
confined to one cerebral hemisphere [1-3]. Seizure fre-
quency may decrease over time, but patients are left
with unilateral hemiparesis and significant cognitive
deficits [4,5]. Histopathologic examination of RE brain
tissue, usually after years of seizures, reveals the pre-
sence of activated microglia and T lymphocytes [6-8].
CD8+ T cells containing granzymes are observed in
close apposition to neurons and astrocytes, but not
oligodendrocytes [6,9]. Auto-antibodies against the
glutamate receptor GluR3, once considered a possible
cause of RE [10], are not present in all RE cases and are
not specific to the disease [11-13]. Circulating anti-
bodies to other neuronal proteins are found in other RE
cases [14-16], leading to the view that a humoral im-
mune response may be a secondary event to T cell im-
munity [6,17]. Thus, RE resembles an autoimmune
disease although the histopathology is also consistent
with an immune response to a virus or other infectious
agent [1,17]. Cytomegalovirus, herpes simplex virus,
and Epstein Barr virus sequences have been detected in
some RE brain specimens, but have not been reprodu-
cibly identified in all cases [18-22]. Neither autoimmunity
nor infection can easily explain the unilateral hemispheric
involvement.
To gain further insight into the immunopathology of
RE, we measured the relative expression of 84 mRNA
transcripts associated with inflammation and autoimmu-
nity in brain tissue from 12 RE and 12 cortical dysplasia
(CD) epilepsy patients. The CD cases constituted a refe-
rence group against which to compare gene expression
levels. Inflammation is associated with CD, but is less
severe than in RE, and T cell involvement is limited
[23,24]. Quantitative differences in transcript levels be-
tween RE and CD specimens were found for several genes
involved in the activation and recruitment of effector T
cells. The highest levels of expression were found in early
stage RE cases.
Methods
Cohort recruitment and clinical variables
Under University of California, Los Angeles, (UCLA) In-
stitutional Review Board (IRB) approval, brain tissue was
collected at surgery as part of UCLA’s Pediatric Epilepsy
Surgery program. Informed consent to use the surgically
resected tissue for research was obtained through the
parents or legal guardians. The 12 RE and 12 CD cases
used in the study were selected with similar ages at sur-
gery. Seven CD cases were classified as CDI, and five as
CDII [25]. The clinical protocols for patient evaluation
and surgical procedures for collection and processing of
cortical specimens have been previously published [26,27].
Clinical variables included, age at seizure onset, age at sur-
gery, and disease progression (age at seizure onset to age
at surgery). Magnetic resonance imaging (MRI) scans
were assessed by one investigator (GWM). A semiquanti-
tative score was assigned to the T2 and FLAIR signal
changes (0 = none, 1 = slight; 2 = mild; 3 = moderate; 4 =
extensive) to estimate the degree of tissue destruction and
inflammation, respectively.
Real-time PCR and analysis
Total RNA was purified from flash frozen blocks of in-
volved tissue consisting of mostly cortical gray matter
(approximately 50 mg) using Trizol™ (Life Technologies,
Carlsbad, CA, USA) and reverse transcribed (Qiagen,
Valencia, CA, USA). PCR reactions were carried out in
an ABI 7300 thermocycler using SYBR™ green chemistry
(SABiosciences, Valencia, CA, USA). The 96-well format
qPCR array contained primers for 84 genes of interest
and 5 reference genes (SABiosciences inflammation and
autoimmunity qPCR array, cat no. PAHS-0077Z). Stand-
ard cycling parameters were used as follows: 1 cycle: 95°C
10 min, 40 cycles: 95°C 15 sec, 60°C 1 min. As part of the
cycling program, all PCR products were thermally dena-
tured and dissociation curves were obtained. Two of the
primer sets resulted in dissociation curves with multiple
peaks (CCL16 and CCL24) and were eliminated from the
analysis. To calculate relative transcript levels, baseline-
subtracted fluorescence values per cycle for each primer
set were entered into LinRegPCR [28] and PCR efficien-
cies (E) and Ct values were determined. The relative
expression of each gene (X0) [29] in each array was calcu-
lated from:
X0 ¼ E−Ct
NormalFinder [30] was used to identify the least variable
housekeeping gene across the 24 arrays. ACTB encoding
β-actin was found to be the most stable reference gene,
and was used to normalize all of the data including the
four other reference genes (HPRT1, RPL13A, GAPDH,
B2M). Samples were grouped by consensus clustering [31]
using the non-negative matrix factorization algorithm [32]
found in the GENE-E bioinformatics package (www.
broadinstitute.org). Statistical analyses utilized R-project
programs (www.r-project.org). Plots were generated
by the Deducer graphical user interface and exported
into CorelDRAW X6 (Corel Corporation, Ottawa, ON,
Canada). Significant differences (P <0.05) in gene expres-
sion between RE and CD cases were determined by pair-
wise comparison of the distribution of transcript levels for
each gene using Harrell-Davis quantile estimators [33,34].
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Immunocytochemistry and image analysis
Paraffin-embedded blocks of involved tissue were serially
sectioned (5 μm), deparaffinized, and microwaved for 20
minutes in buffered citrate (10 mM, pH 6.0) for antigen
retrieval. After one hour in blocking solution (Impress
Kit, Vector Laboratories, Burlingame, CA, USA) sections
were incubated overnight at 4°C with rabbit anti-human
CD4 (1:250, Novus Biologicals, Littleton, CO, USA) or
mouse anti-human CD8 (1:100, Dako, Carpinteria, CA,
USA). Sections were immunostained for one hour at 25°C
with peroxidase-conjugated anti-rabbit or anti-mouse
secondary antibodies (Impress Kit, Vector Laboratories)
Table 1 Summary of clinical variables for Rasmussen encephalitis (RE) and cortical dysplasia (CD) cohorts
Clinical variable RE (n = 12) CD (n = 12) P value
Age at surgery (years) 9.9 ± 3.1 9.2 ± 3.6 P = 0.621a
Age at seizure onset (years) 6.4 ± 3.1 2.8 ± 2.4 P = 0.005a
Time from onset to surgery (years) 3.5 ± 3.5 6.5 ± 3.3 P = 0.047a
Number of AED pre-surgery 3 ± 1 3 ± 1 P = 0.248a
Side (Left/Right) 4/8 6/6 P = 0.408b
Gender (Female/Male) 5/7 8/4 P = 0.219b
T2 Index 2.5 0 P= 0.016c
FLAIR Index 2 1 P = 0.003c
Mean ± SD or median values are shown. P values calculated as at-test.
bChi square or cMann-Whitney. AED, antiepileptic drugs; FLAIR, fluid attenuated inversion recovery.
Table 2 Clinical variables associated with Rasmussen encephalitis and cortical dysplasia patient specimens















RE1 M 4 4.75 0.75 2 RE Right Hemispherectomy 1 4
RE2 F 6.7 7.5 0.8 5 RE Right Hemispherectomy 3 1
RE3 F 4.5 10 5.5 4 RE Right Hemispherectomy 2 1
RE4 M 2.5 10 7.5 3 RE Left Hemispherectomy 1 1
RE5 M 9.25 10.5 1.25 3 RE Left Hemispherectomy 3 2
RE6 F 8 13 5 0 RE Right Hemispherectomy 4 3
RE7 M 12 13.5 1.5 4 RE Left Hemispherectomy 1 2
RE8 M 8 10.1 2.1 2 RE Right Hemispherectomy 2 1
RE9 F 4.1 6.25 2.15 4 RE Right Hemispherectomy 3 2
RE10 F 10 12.2 2.2 4 RE Right Hemispherectomy 3 3
RE11 M 2 14.4 12.2 4 RE Left Hemispherectomy 3 2
RE12 M 5.3 6.3 1 2 RE Right Hemispherectomy 1 1
CD1 F 5 14.2 9.2 2 CD1 Right Temporal 1 1
CD2 F 0.75 3.2 2.45 2 CD1 Left Frontal-Parietal 0 0
CD3 F 1.5 10.2 8.7 3 CD1/HS Left Temporal 0 1
CD4 F 3 6.5 3.5 1 CD1 Right Temporal 1 1
CD5 F 1.4 9 7.6 4 CD Right Frontal 1 1
CD6 F 9 12.3 3.3 3 CD2A Left Temporal 1 1
CD7 F 3 8.5 5.5 2 CD2A Right Temporal 0 0
CD8 M 2.3 14.5 12.2 3 CD1 Left Temporal-Parietal 0 1
CD9 M 0.1 5.2 5.1 2 CD1 Left Parietal 0 1
CD10 F 0.75 9.3 8.55 4 CD1 Right Hemispherectomy 0 0
CD11 M 3 12 9 3 CD2B Left Parietal 2 1
CD12 M 3.5 5.25 1.75 1 CD1 Right Hemispherectomy 0 0
aEvaluation of T2 and FLAIR signal changes on scales of 0 to 4.
AED, antiepileptic drugs; CD, cortical dysplasia; FLAIR, fluid attenuated inversion recovery; HS, hippocampal sclerosis; RE, Rasmussen encephalitis.
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followed by incubation with 3,3′-diaminobenzidine (DAB)
substrate (MP Biomedicals, Santa Ana, CA, USA), then
counterstained with hematoxylin. Sections of tonsil tissue
were used as positive controls, and omission of primary
antibodies served as negative controls. Images of entire
sections were acquired with an Aperio ScanScope XT
scanner (Aperio, Vista, CA, USA) and transferred to
CorelDRAWX6. Strong DAB staining of CD4 and CD8
immunoreactive cells was quantified using the positive
pixel count algorithm, part of the Aperio ImageScope soft-
ware package.
Western blotting
Blocks of flash frozen involved tissue were homogenized
in RIPA buffer containing protease and phosphatase
inhibitors (Sigma-Aldrich, St. Louis, MO, USA). Lysates
were separated on precast 10% polyacrylamide gels
(Biorad, Hercules, CA, USA) and transferred to PVDF
membranes (Biorad). Prestained molecular standards were
used (Biorad). The membrane was blocked in Tris-
buffered saline (pH 7.4) containing 5% nonfat dried milk
and 0.1% Tween™ 20, and probed with a monoclonal anti-
body to hypoxanthine-guanine phosphoribosyltransferase
(anti-HPRT 1:1000, Proteintech Group Inc., Chicago, IL,
USA). Proteins were visualized with a secondary antibody
conjugated to horseradish peroxidase (1:2500, Jackson
ImmunoResearch Laboratories, West Grove, PA, USA)
using a chemiluminescent substrate (Thermo-Scientific,
Waltham, MA, USA). The blot was stripped and re-probed
with a monoclonal antibody to glyceraldehyde 3-phosphate
dehydrogenase (anti-GAPDH 1:1000, Stressgen, Victoria,
BC, Canada). X-ray films were scanned and processed
(background subtraction and enhancement using default
settings) in Image J, and exported to CorelDRAWX6.
Figure 1 Examples of magnetic resonance imaging (MRI) scans from patients with Rasmussen encephalitis (RE) or cortical dysplasia
(CD). Scans were semiquantitatively assessed for T2 (A and C) and FLAIR (B and D) signal changes. The RE case (A and B) was a 13 year old with
a five-year history of seizures originating from the right hemisphere. The T2 image was scored severe (4) for tissue destruction (A), and moderate
(3) for amount of FLAIR changes (B). The patient with CD (C and D) had abnormality localized to the left parietal area (arrows). The MRI scans
were scored zero (no increased signal changes) for T2 (C) and FLAIR changes (D) despite the abnormal anatomy.
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Results
Rasmussen encephalitis and cortical dysplasia patient
cohorts
Table 1 summarizes clinical variables for the RE (n = 12)
and CD (n = 12) cohorts selected for study. Patient data
associated with each specimen are provided in Table 2.
The age range at surgery was similar, whereas seizure on-
set occurred at an earlier age in the CD compared with
the RE cohort, thus time from seizure onset to surgery
also differed. Other clinical parameters were not signifi-
cantly different, except for the extent of tissue destruction
and inflammation measured by changes in the T2-
weighted and FLAIR MRI scans, respectively. These
parameters were scored semiquantitatively and reflect
more injury/inflammation in RE compared with CD cases
(Tables 1 and 2). Figure 1 shows examples of graded MRI
scans from an RE (A and B) and CD patient (C and D).
A subset of inflammatory genes distinguishes Rasmussen
encephalitis from cortical dysplasia
We obtained normalized expression data for 86 genes (82
inflammatory and 4 housekeeping genes). Transcripts of
71 genes were detected in every specimen, confirming that
inflammatory genes are expressed in both RE and CD
[24]. Thirteen of the remaining genes were expressed in at
least six RE specimens, and were retained for analysis.
IL23R and IL1F10 transcripts were detected in only three
of the RE specimens and were eliminated, leaving a total
of 84 genes. IL23R transcripts were expressed in four of
the CD cases, and IL1F10 expression was not detected in
any of the CD cases.
We employed a consensus clustering method to
organize the blinded samples into two groups. Half of the
RE cases (RE1, 2, 5, 6, 10, 12) segregated from the 12 CD
specimens, two (RE3, 9) partially segregated, and the
remaining four (RE4, 7, 8, 11) could not be distinguished
from the CD cases (Figure 2). Thus, 6 of 12 RE cases
could be clearly identified based solely on the array data.
Sample heterogeneity may partly explain why not all of
the RE cases clustered. On the other hand, the six clus-
tered RE cases may indicate differences related to clinical
variables such as disease progression [35].
Although the clustering analysis revealed variability
within the RE cohort, we proceeded to examine whether
the expression of particular genes differed between the RE
and CD cohorts. The distribution of transcript levels of 40
genes in the RE set and 36 genes in the CD set did not sat-
isfy the Shapiro-Wilk normality test (P <0.05); >85% of
these genes showed P values of <0.01. Therefore pairwise
comparisons were carried out using the Harrell-Davis
distribution-free quantile estimator method. This gener-
ates robust analyses that are well-protected from viola-
tions of normality. The analysis uses an adjusted critical
value for determining significance that controls for mul-
tiple comparisons. Distributions were divided into deciles.
Transcript levels of eight genes were significantly different
between the RE and CD samples across all quantiles
(P <0.05; [see Additional file 1: Table S1]). Seven genes
were expressed at higher levels in the RE samples; whereas
hypoxanthine-guanine phosphoribosyltransferase (HPRT)
mRNA levels were reduced (Figure 3). Western blot ana-
lysis showed less HPRT protein in tissue lysates that were
available from two of the RE specimens compared with
one of the CD specimens (Figure 4). The other house-
keeping genes did not differ between the RE and CD
groups [see Additional file 1: Table S1]).
Four of the seven genes with higher expression in the
RE specimens, that is, the cytokine IFN-γ, and the
chemokines, CCL5/RANTES (regulated and normal T
cell expressed and secreted), CXCL9/MIG (monokine
induced by IFN-γ), CXCL10/IP-10 (IFN-γ-induced pro-
tein 10), play a role in T cell-mediated immunity (see
Discussion). Relative expression levels of these genes in
the RE cohort were highly positively correlated with each
other (Table 3); the lower amounts of these transcripts








































































Figure 2 Consensus clustering applied to qPCR array
expression data from Rasmussen encephalitis (RE) and cortical
dysplasia (CD) specimens. Non-negative matrix factorization was
used to determine whether the mRNA expression data could
distinguish between RE and CD. With k = 2 clusters, six of the RE
cohort were clearly predicted. Two RE cases partially segregated, and
the remaining four could not be differentiated from the CD cohort.
Heat map is scaled from high (red) to low (white) correlation
between samples.
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remaining genes encode two other chemokines, CCL22/
MDC (macrophage derived chemokine) and CCL23/
MIP-3 (macrophage inflammatory protein 3), and Fas
ligand (FasL). FasL mRNA levels positively correlated
with IFN-γ, CCL5, and CXCL9 mRNA levels (Table 3);
correlation between FasL and CXCL10 did not quite
reach the threshold for significance. The amounts of
CCL22 and CCL23 mRNA did not correlate with ex-
pression of the other genes (Table 3).
Inflammatory gene expression correlated with clinical
parameters
We next asked whether the expression of the seven in-
flammatory genes associated with RE correlated with
clinical variables (Table 1). Time from seizure onset to
surgery, a measure of disease progression, negatively
correlated with mRNA levels for IFN-γ, CCL5, CXCL9
and CXCL10 (P <0.05; Table 3). By contrast, in the CD






























































































































































Figure 3 Expression levels of genes that were significantly different between Rasmussen encephalitis (RE) and cortical dysplasia
specimens. Stacked dot plots of normalized expression values for each sample are shown. Solid circles identify the six RE specimens separable
by consensus clustering (Figure 2); open circles identify the remaining RE cases. The RE sample with the highest inflammatory gene transcript
level is indicated.
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correlated with time from seizure onset to surgery
(P <0.05; Table 4). Positive correlations were found com-
paring FasL mRNA and severity of inflammation, and
CCL23 levels and tissue destruction as assessed by
FLAIR and T2 MRIs, respectively (Table 3). As shown in
Figure 5A and 5B, the data for IFN-γ and CXCL9 best
fit nonlinear functions. Of the six RE cases identified by
consensus clustering, five correspond to the earliest
times points (filled circles in Figure 5A and 5B),
suggesting that an early highly inflammatory phase dis-
tinguishes RE from CD. The FasL and CCL23 results are
best described by linear functions (Figure 5C and 5D).
The number of antiepileptic drugs that the RE and CD
patients were receiving at the time of surgery did not
significantly correlate with the expression of any of the
seven inflammatory genes (Tables 3 and 4).
T cell infiltration in Rasmussen encephalitis brain
correlated with levels of inflammatory genes
Based on our findings we predicted that a more pro-
nounced T cell infiltration would be evident in tissue
specimens with higher expression of IFN-γ mRNA. Sec-
tions from blocks that were available from seven of the 12
RE specimens were immunostained for CD4 and CD8 ex-
pression (four from the group of six with the highest levels
of IFN-γ mRNA: RE1, RE2, RE5, and RE10, and three
from the remaining specimens: RE3, RE4, and RE8).
Quantitation of the strongly immunoreactive cells in digi-
tized images of the stained sections revealed that there
were more CD4+ and CD8+ T cells in sections from three
out of the four cases with higher IFN-γ and related che-
mokine mRNA expression (Figure 6; filled circles). CD4+
T cells were associated with clusters of CD8+ T cells, but
were mainly concentrated in leptomeninges and perivas-
cular (Virchow-Robin) spaces, which contained fewer
CD8+ T cells (Figure 7).
Discussion
We used a qPCR array to measure inflammatory gene ex-
pression in 12 RE specimens and 12 CD specimens, and
then correlated the expression of genes that differed be-
tween the two groups with clinical parameters. Selection
of the CD specimens from the UCLA Pediatric Surgery
Program’s tissue bank was based on choosing patients
whose ages at surgery were approximately the same as the
much rarer RE cases that took approximately ten years to
accrue. There were no other exclusion criteria. The array
included genes encoding pro-inflammatory T helper 1
(Th1) and anti-inflammatory T helper 2 (Th2) cell cyto-
kines, chemokines, Toll-like receptors and other factors
involved in downstream signaling. The expression levels
of only eight transcripts significantly differed between the
RE and CD specimens. With the exception of HPRT
mRNA, the transcripts were expressed at higher levels in
the RE specimens. Reduced HPRT, a housekeeping gene
Figure 4 Hypoxanthine-guanine phosphoribosyltransferase
(HPRT) protein levels differ between Rasmussen encephalitis
(RE) and cortical dysplasia (CD) specimens. Western blot showing
lower amounts of HPRT in two RE samples (RE1 and RE2) compared
with a reference CD specimen (CD5). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as a loading control.
Table 3 Cross-correlation matrix (Spearman rank correlation coefficients) generated by comparing gene expression
levels with clinical parameters of the Rasmussen encephalitis cohort
CCL5 CCL22 CCL23 CXCL9 CXCL10 FasL FLAIR IFN-γ T2 Time AED
CCL5 1.00 0.66a 0.31 0.73 0.64 0.83 0.12 0.94 0.17 −0.62 0.07
CCL22 1.00 0.06 0.54 0.54 0.22 −0.44 0.5 −0.08 −0.54 0.28
CCL23 1.00 0.12 −0.08 0.50 0.44 0.28 0.64 −0.21 0.08
CXCL9 1.00 0.92 0.63 0.01 0.82 −0.24 −0.82 −0.07
CXCL10 1.00 0.53 0.00 0.73 −0.33 −0.69 0.00
FasL 1.00 0.60 0.87 0.25 −0.54 −0.02
FLAIR 1.00 0.19 0.31 −0.09 −0.19
IFN-γ 1.00 0.07 −0.64 −0.09
T2 1.00 0.27 0.18
Timeb 1.00 0.12
AED 1.00
aStatistically significant correlations are in bold type (P < 0.05). bTime from seizure onset to surgery.
AED, antiepileptic drugs.
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on the array, was unexpected and may reflect disease-
associated atrophy. Alternatively, a reduced level of HPRT
in brain tissue may be significant since a decrease in this
enzyme would be expected to affect purine metabolism,
with possible effects on brain function [36]. Analysis of
HPRT protein levels in more RE samples will be
necessary to establish the significance of this finding to
the disease process.
In RE there is clear histopathologic evidence for the
involvement of CD8+ T cells in the disease process
[6-8,23]. In agreement with these data, four of the seven
genes whose mRNA levels were higher in RE compared
Table 4 Cross-correlation matrix (Spearman rank correlation coefficients) generated by comparing gene expression
levels with clinical parameters of the cortical dysplasia cohort
CCL5 CCL22 CCL23 CXCL9 CXCL10 FasL FLAIR IFN-γ T2 Time AED
CCL5 1.00 −0.16 0.26 0.3 0.06 0.17 −0.02 0.06 −0.15 0.36 0.43
CCL22 1.00 −0.01 −0.02 0.06 0.08 0.04 0.03 −0.4 0.03 −0.31
CCL23 1.00 0.3 −0.19 0.57 0.21 0.1 0.16 0.12 0.22
CXCL9 1.00 0.08 0.49 0.16 −0.46 −0.1 −0.05 0.08
CXCL10 1.00 −0.12 −0.26 −0.2 −0.42 0.13 0.04
FasL 1.00 0.37 −0.15 0.39 0.23 0.56
FLAIR 1.00 0.18 0.41 0.57 0.25
IFN-γ 1.00 −0.04 0.62a 0.31
T2 1.00 0.18 0.13
Timeb 1.00 0.51
AED 1.00








































































FLAIR (index) T2 (index)
1.0 1.5 2.0 2.5 3.0 3.5 4.0 1.0 1.5 2.0 2.5 3.0 3.5 4.0
2.0 10.04.0 6.0 8.0 12.00.0 2.0 10.04.0 6.0 8.0 12.00.0
A B
C D
Figure 5 Correlations between clinical parameters and gene expression. Transcript levels of four of the inflammatory genes that were
expressed at a significantly higher level in the Rasmussen encephalitis (RE) compared with cortical dysplasia specimens were plotted against
clinical parameters. Negatively correlated parameters are best described by non-linear inverse functions (A and B), whereas linear functions can
be fitted to the positively correlated parameters (C and D). Solid circles identify the six RE specimens separable by consensus clustering (Figure 2);
open circles identify the remaining RE cases.
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with CD cases encode proteins involved in Th1-driven
immune responses, namely IFN-γ, CCL5, CXCL9 and
CXCL10. Activated CD8+ cytotoxic T cells (Tc1) and
CD4+ Th1 cells produce IFN- γ [37,38], thus infiltrating
CD8+ T cells in neuropil and CD4+ T cells in Virchow-
Robin spaces and leptomeninges (Figure 7) could be
sources of IFN-γ transcripts in the RE brain specimens.
Although the immunopathology in RE appears to be
driven by Tc1 cells, CD4+ cells, in the perivascular space
may play a role in sustaining Tc1 activity [39-41]. Nat-
ural killer (NK) cells, NKT cells, and γδ T cells produce
IFN-γ [37,42], which may also account for the IFN-γ
transcripts in RE tissue. To date, we and others have
found no evidence for significant numbers of NK cells in
RE brain tissue [7]. However, we have recently identified
γδ T cells in brain infiltrating lymphocytes isolated from
fresh RE brain tissue (unpublished data).
IFN-γ can induce major histocompatibility complex
(MHC) class I molecules on the surface of neurons, ren-
dering them vulnerable to attack by autoantigen-sensitized
MHC class I-restricted Tc1 cells [43]. Further, IFN-γ has
been shown to induce bursting of hippocampal pyramidal
neurons in vitro [44], providing a possible link between T
cells and epileptogenesis.
It has been reported that IFN-γ induces the produc-
tion of CXCL9 by microglia and CXCL10 by microglia
and astrocytes [45], and promotes IL-1-induced synthe-
sis of CCL5 by astrocytes [46]. The positive correlation
between the relative amounts of CXCL9, CXCL10, CCL5













Figure 6 Relative numbers of CD4+ and CD8+ T cells in sections
taken from 7 of the 12 Rasmussen encephalitis (RE) cases.
Digitized images from serial sections immunostained with anti-CD4
and anti-CD8 were quantified, and indicate higher numbers of both
CD4+ and CD8+ T cells in three of four RE cases identified by
consensus clustering (filled circles) compared to three RE cases that
were not distinguished from cortical dysplasia (open circles).
Figure 7 Photomicrographs showing CD4+ and CD8+ immunoreactivity in Rasmussen encephalitis (RE) specimens. Adjacent sections
from specimens expressing high chemokine mRNA levels show a greater concentration of CD4+ T cells than CD8+ T cells within leptomeninges
(A and B) and perivascular spaces (C and D), and fewer CD4+ T cells (E) within clusters of CD8+ T cells in brain parenchyma (F). Images are taken
from specimens RE2 (A and B), and RE10 (C-F). Scale bars correspond to 50 microns (A and B), and 25 microns (C-F).
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specimens is consistent with these reports. All three
chemokines have been implicated in attracting Th1, Tc1,
γδ T cells and NK cells to sites of inflammation [47].
The presence of CXCR3, the receptor for CXCL9 and
CXCL10 [48], and CCR5 (CCL5 receptor) on infiltrating
T cells in brain sections from a single RE case has been
documented [49]. Other single patient studies have pro-
vided evidence for the expression of CCL5 and CXCL10
in RE brain tissue [50,51].
Quantitative PCR allowed correlations to be made be-
tween the amount of inflammatory gene transcripts and
clinical variables. Notably, much higher levels of IFN-γ
and CXCL9 mRNAs were detected in specimens from
patients that had undergone surgery within shorter times
from disease onset compared to later times. This sug-
gests that there is a pronounced Th1 immune response
in the early phase of the disease that declines after 1 to 2
years. The observation of large numbers of CD4+ and
CD8+ lymphocytes in sections from specimens in which
high levels of IFN-γ mRNA were detected is consonant
with an initial Th1 polarized response. In support of
these data, it was previously reported that cerebrospinal
fluid levels of IFN-γ were higher in the earlier stages of
RE [52].
A role for the Fas/FasL-mediated cell death pathway in
RE is indicated from the qPCR data. Based on the observa-
tion of granzyme B immunoreactivity in T cells in close ap-
position to neurons and astrocytes, it has been suggested
that MHC class I-restricted killing occurs by the perforin
lytic pathway [6,9]. However MHC class I-restricted killing
of neurons can also occur by Fas ligand-induced apoptosis
[53]. On the other hand, the detection of FasL transcripts
in the present study could be explained by activation-
induced cell death of activated T cells in the brain [54]. In
experimental autoimmune encephalitis, astrocytes express-
ing FasL have been implicated in T cell homeostasis [55].
In contrast to the chemokines associated with a Th1
response, CCL22, which binds CCR4 [56], is associated
with a Th2 polarized response, which can facilitate B cell
activation [38]. The finding of higher levels of this che-
mokine in RE brain tissue is therefore consistent with
the presence of circulating antibodies to neuronal pro-
teins in some RE patients [10,11,14-16]. Unlike the Th1
cytokines, CCL22 expression did not strongly correlate
with time from disease onset to surgery, supporting the
notion that a B cell response may be a secondary conse-
quence of tissue destruction mediated by Tc1 cells [17].
CCL22 may also be involved in recruiting immunosup-
pressive T regulatory cells into the brain to modulate the
Tc1 response [57].
A positive correlation was observed between the extent
of tissue destruction as measured by MRI and the level of
CCL23 mRNA. CCL23 can act as a chemoattractant for
monocytes [58]. A role for monocytes in RE pathogenesis
is therefore possible as is the case in viral encephalitis
[59]. Since monocytes also produce vascular endothelial
growth factor [60], this may explain the vascular changes
that have been observed in resected RE but not CD brain
tissue [61].
Conclusions
Local inflammation of the brain is seen in both RE and
CD, however quantitative differences in a small set of
genes associated with inflammation and autoimmunity
can clearly distinguish early phase RE cases from CD. In
RE brain tissue, the levels of IFN-γ, CXCL9, CXCL10 and
CCL5 mRNA were inversely related to the length of time
between disease onset and surgery, suggesting a pro-
nounced Th1 response in the early symptomatic phase of
the disease. Differences in the number of CD4+ and CD8+
T cells in brain sections from the same cases supported
this conclusion. An unresolved Th1 response can lead to
autoimmunity [62], and this may explain the persistent
inflammation, presence of circulating antibodies to neur-
onal proteins, and tissue destruction in RE. One outcome
of the present study is the suggestion that blockade of
chemokines could constitute a new therapeutic avenue for
controlling RE disease progression [63].
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